Elbasvir / Grazoprevir: 9 agencies, 2016–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused elbasvir / grazoprevir: all 6 decisive outcomes across 6 agencies were positive or positive with restrictions.
Assessment has run over 6 years, from 7 Jul 2016 at AWMSG (Wales) to 19 Jul 2022 at AWMSG (Wales).
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for elbasvir / grazoprevir by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess elbasvir / grazoprevir, on 7 Jul 2016; PBAC (Australia) did not open a file until 2018 — a moderate spread of 2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 10 dated records fall in 2016 alone.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed elbasvir / grazoprevir to a subgroup rather than accepting or refusing it outright, at NYE METODER (Norway) and TLV (Sweden).
2 of the 9 agencies here assessed elbasvir / grazoprevir more than once, AWMSG (Wales) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for elbasvir / grazoprevir.
The full ledger for elbasvir / grazoprevir reads 4 recommended, 2 no benefit, 2 restricted and 1 deferred, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 19 Jul 2022 | Treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg | recommended (licence extension for paediatric use) | source |
| G-BA (Germany) | 5 May 2022 | Zepatier — benefit assessment §35a | added benefit: not proven | source |
| PBAC (Australia) | 2018 | Chronic Hepatitis C virus (HCV) infection | The PBAC deferred making a recommendation on amending the listing of grazoprevir with elba… | source |
| CONITEC (Brazil) | 15 Mar 2018 | Tratamento de adultos com hepatite C crônica infectados pelos genótipos 1 e 4 | incorporated into SUS | source |
| SMC (Scotland) | 16 Jan 2017 | Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not … | accepted | source |
6 further decisions for elbasvir / grazoprevir, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- sofosbuvir / velpatasvir / voxilaprevir — divergent outcome (recommended vs no benefit) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 11 decisions for elbasvir / grazoprevir from 9 agencies, 2016 to 2022. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.